DeFi Development Corp. Delivers Record Month with Key Integrations, Treasury Growth, and Institutional Partnerships
BOCA RATON, FL, June 02, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first US public company with a treasury strategy built…
Semilux Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 20-F
Taipei, Taiwan, June 02, 2025 (GLOBE NEWSWIRE) -- Semilux International Ltd. (NASDAQ:SELX) (“SELX” or the “Company”) announced that it received a delinquency notification letter on May 27, 2025 (the “Deficiency…
Extendicare Acquires Nine Long-Term Care Homes from Revera
MARKHAM, Ontario, June 02, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare”) (TSX: EXE.TO) announced today that, effective June 1, 2025, it has completed the previously announced transaction with Revera Inc.…
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance
Novonesis has successfully completed the acquisition of dsm-firmenich’s share of the Feed Enzyme Alliance following the satisfaction of all closing conditions. The acquisition was initially announced on February 11, 2025…
Form 8.3 – [CRANEWARE PLC – 30 05 2025]
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a)…
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-‘749 (olanzapine) to Date
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS…
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreatedLTC residents are often…
Snail Inc. 旗下独立品牌 Wandering Wizard 与拉丁美洲工作室 Seven Leaf Clover 达成发行合作，加速全球市场布局
加利福尼亚州卡尔弗城, May 31, 2025 (GLOBE NEWSWIRE) -- 全球领先的互动数字娱乐领域独立开发商与发行商 Snail, Inc. (Nasdaq: SNAL，以下简称 “Snail Games” 或 “公司”) 宣布，其独立游戏发行品牌 Wandering Wizard 已与阿根廷开发商 Seven Leaf Clover 达成发行合作协议，获得高强度第一人称单人射击游戏 (FPS) Rebel Engine 的发行权。 Rebel Engine…
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Press Release dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025 dsm-firmenich, innovators in nutrition, health, and…
Snail Inc. 旗下獨立品牌 Wandering Wizard 與拉丁美洲工作室 Seven Leaf Clover 建立發行合作夥伴關係，擴大在全球市場的影響力
加利福尼亞州卡爾弗城, May 31, 2025 (GLOBE NEWSWIRE) -- 全球領先的互動數碼娛樂獨立開發商及發行商 Snail, Inc. (Nasdaq: SNAL)（「Snail Games」或「公司」）宣布其獨立發行品牌 Wandering Wizard，與來自阿根廷的開發商 Seven Leaf Clover 建立發行合作夥伴關係，以獲取極具影響力、單人第一人稱射擊（「FPS」）遊戲 《Rebel Engine》 的發行權利。 遊戲預計將於 2025 年在 PC 平台上發行，該公司預計 《Rebel Engine》 將進一步擴大…